Since 2003, Prof. Wang began to participate in clinical trials of related domestic and international pharmaceutical companies, and published international papers in accordance with the relevant procedures of clinical trials, for the cardiovascular disease prognosis research of GLP-1 receptor agonist of EXCEL and HARMONY. The papers were published in New England Journal of Medicine, one of the co-authors. He is also one of the co-authors of the international CVDREAL-3 study published in Lancet Endocrinology and Diabetes. He also participated in the second phase of clinical trials of new drugs in China, and was the first author of related research on new drug treatments for diabetes published in the Journal of Clinical Endocrinology & Metabolism. At present, related diabetes blood sugar monitoring technology is also being carried out, as well as the genetic research of thyroid cancer in cooperation with the National Institutes of Health. 2. On the other hand, it has been the lifelong honor and privilege to serve as an endocrinologist, stated by Prof. wang, dedicating to advancing research in thyroid disorders and diabetes. Over the past three decades, had focused not only diabetes but particularly on both laboratory research and clinical practice in the areas of thyroid cancer and autoimmune thyroid diseases. Clinically, thyroid cancer is a low-grade endocrine malignancy with a relatively long survival time. Most patients undergo thyroidectomy and radioactive iodine-131 therapy. Postoperatively, thyroid cancer patients are followed up using thyroid ultrasound examinations and continuous serum thyroglobulin assessments. Previous studies have shown that one-third of well-differentiated thyroid cancers may transform into poorly differentiated forms during disease progression, potentially becoming fatal malignancies. At this stage, the effectiveness of surgery, chemotherapy, and external radiation therapy is not significant. Given the above, effective treatment strategies and follow-up methods are crucial, including complete surgical removal of thyroid cancer with lymph node dissection, radioactive iodine-131 therapy, and monitoring of thyroid tumor biomarkers. In some cases, papillary and follicular thyroid cancers may gradually undergo dedifferentiation, with anaplastic thyroid cancer being the ultimate result. The research team has been conducting fundamental research and investigated initiated clinical trials on thyroid cancer for over 15 years and has published numerous international journal articles on thyroid cancer cell and animal model experiments (e.g., Cancer 2002; 95:1827-1833, Endocrinology 2003; 144:3852-3859, J Clin Endocrin Metab 2003; 88:3021-3026, Endocr Relat Cancer 2005; 12:615-29, Intern J Cancer 2010; 126(2):578-82, J Proteomics 2012; 75(4):1170-80, J Invest Med 2018; 66(5):1-9, Frontiers in Endocrinology 2020; 11:382). During our research, we found that prognosis monitoring of thyroid cancer patients will be one of the most significant clinical research topics.

Vertis-CV Emap-Reg Rio-Asia Rio-CV